Aurobindo Pharma gets USFDA nod for cancer treatment injection – ET HealthWorld

New Delhi: Drug firm Aurobindo Pharma on Friday said its arm Eugia Pharma Specialties have received approval from the US health regulator for Cyclophosphamide injection, used in the treatment of several types of cancer. The company’s subsidiary “Eugia Pharma Specialties Ltd has received a 505(b)(2) NDA approval from the US Food & Drug Administration (USFDA) for its Cyclophosphamide Injection 500 mg/2.5 mL and 1 g/5 mL vial,” Aurobindo Pharma said in a regulatory filing.

The product will be available in ready-to-use injection preparation, it added.

“The product shall be launched in the US market in the near term and will be manufactured in Eugia’s manufacturing facility in India,” Aurobindo Pharma said.

According to IQVIA, the approved product has an addressable market size of USD 170 million for the twelve months ending June 2021, it added.

Cyclophosphamide Injection is indicated for malignant lymphomas, multiple myeloma, leukemia, mycosis fungoides, neuroblastoma, adenocarcinoma of the ovary, retinoblastoma and carcinoma of the breast, the filing said.

This is the 19th product to be approved (including 3 tentative approvals) for Eugia. Aurobindo now has a total of 482 abbreviated new drug application (ANDA) approvals (453 final approvals and 29 tentative approvals) from the USFDA, it added.

Shares of Aurobindo Pharma was trading at Rs 709 per scrip on BSE, up 1.56 per cent from its previous close.


Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please Remove AdBlocker